User:Longnat/sandbox
 | This is a user sandbox of Longnat. You can use it for testing or practicing edits. This is not the sandbox where you should draft your assigned article for a dashboard.wikiedu.org course. To find the right sandbox for your assignment, visit your Dashboard course page and follow the Sandbox Draft link for your assigned article in the My Articles section. |
Yttrium-90
[edit]| General | |
|---|---|
| Symbol | 90Y |
| Names | longnat/sandbox, 90Y, Y-90 |
| Protons (Z) | 39 |
| Neutrons (N) | 51 |
| Nuclide data | |
| Half-life (t1/2) | 64.60 h |
| Isotopes of yttrium Complete table of nuclides | |
Yttrium-90, 90
Y
, is an isotope of yttrium.[2] Yttrium-90 has found a wide range of uses in radiation therapy to treat some forms of cancer.[3]
Decay
[edit]90
Y
undergoes β− decay to zirconium-90 with a half-life of 64.1 hours[3] and a decay energy of 2.28 MeV.[4] It also produces 0.01% 1.7 MeV[5] photons during its decay process. The interaction between emitted electrons and matter can lead to the emission of Bremsstrahlung radiation.
Production
[edit]Yttrium-90 is produced by the nuclear decay of strontium-90 which has a half-life of nearly 29 years and is a fission product of uranium used in nuclear reactors. As the strontium-90 decays, chemical high-purity separation is used to isolate the yttrium-90 to be precipitated.[6][7]
Medical application
[edit]90Y plays a significant role in the treatment of hepatocellular carcinoma (HCC), leukemia, and lymphoma, although it has the potential to treat a range of tumors.[8][9] Trans-arterial radioembolization is a procedure performed by interventional radiologists in which microspheres are impregnated with 90Y and injected into the arteries supplying the tumor.[10] The microspheres become lodged in blood vessels surrounding the tumor and the resulting radiation damages the nearby tissue.[11] Radioembolization with 90Y significantly prolongs time-to-progression (TTP) of HCC,[12] has a tolerable adverse event profile, and improves patient quality of life more than do similar therapies.[13] 90Y has also found uses in tumor diagnosis by imaging the Bremsstrahlung radiation released by the microspheres.[14]
See also
[edit]References
[edit]- ^ Chetham-Strode, A.; Kinderman, E. M. (February 1, 1954). "The Half-Life of Yttrium-90". Physical Review. 93 (5): 1029. doi:10.1103/physrev.93.1029. ISSN 0031-899X.
- ^ Vincent T. DeVita; Theodore S. Lawrence; Steven A. Rosenberg; Robert A. Weinberg; Ronald A. DePinho (1 April 2008). DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology. Lippincott Williams & Wilkins. p. 2507. ISBN 978-0-7817-7207-5. Retrieved 9 June 2011.
- ^ a b "Y-90 Handling Precautions" (PDF). Retrieved 2015-07-15.
- ^ "Table of Isotopes decay data". The Lund/LBNL Nuclear Data Search. February 1999. Retrieved 2012-10-23.
- ^ Rault, E.; Vandenberghe, S.; Staelens, S.; Lemahieu, I. (2009). Optimization of Yttrium-90 Bremsstrahlung Imaging with Monte Carlo Simulations. 4th European Conference of the International Federation for Medical and Biological Engineering. Vol. 22. pp. 500–504. Retrieved 21 October 2013.
- ^ Hnatowich, D.J.; Chinol, M. (September 1987). "Generator Produced Ytrium-90 for Radioimmunotherapy" (PDF). Journal of Nuclear Medicine – via Citeseerx.
- ^ "PNNL: Isotope Sciences Program - Yttrium-90 Production". PNNL. February 2012. Retrieved 2012-10-23.
- ^ "Yttrium 90 - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 2019-10-21.
- ^ Tong, Aaron K T; Kao, Yung Hsiang; Too, Chow Wei; Chin, Kenneth F W; Ng, David C E; Chow, Pierce K H (2016-03-24). "Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry". The British Journal of Radiology. 89 (1062): 20150943. doi:10.1259/bjr.20150943. ISSN 0007-1285. PMC 5258157. PMID 26943239.
{{cite journal}}: CS1 maint: PMC format (link) - ^ Kallini, Joseph Ralph; Gabr, Ahmed; Salem, Riad; Lewandowski, Robert J. (April 2, 2016). "Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma". Advances in Therapy. 33 (5): 699–714. doi:10.1007/s12325-016-0324-7. ISSN 0741-238X. PMC 4882351. PMID 27039186.
- ^ "Understanding SIR-Spheres Y-90 Resin Microspheres". Colorectal Cancer Alliance. Retrieved 2019-10-21.
- ^ Salem, Riad; Gordon, Andrew C.; Mouli, Samdeep; Hickey, Ryan; et al. (2016). "Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma". Gastroenterology. 151 (6): 1155–1163.e2. doi:10.1053/j.gastro.2016.08.029. ISSN 0016-5085. PMC 5124387. PMID 27575820.
- ^ Salem, Riad; Gilbertsen, Margaret; Butt, Zeeshan; Memon, Khairuddin; et al. (2013). "Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization". Clinical Gastroenterology and Hepatology. 11 (10): 1358–1365.e1. doi:10.1016/j.cgh.2013.04.028. ISSN 1542-3565. PMID 23644386.
- ^ Nakajima, Takahito (2015-04-22). "Theranostic Imaging of Yttrium-90". www.hindawi.com. Retrieved 2019-10-14.
{{cite web}}: CS1 maint: url-status (link)
External links
[edit]- CID {{{1}}} from PubChem